July 14, 2025BMC CancerOpen Access

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

ASAslam SyedWest Virginia University HRHasan RazaBahauddin Zakariya University HKHameer Khan KhaskheliILMA University

Discussion

Member takes

Implication

Meta-analysis reveals no significant benefit of immunotherapy-docetaxel combinations on overall survival in mCRPC, suggesting further trials are needed.

Key Points

MAIN FINDING: Immunotherapy and docetaxel combinations show no significant advantage over docetaxel alone in metastatic castration-resistant prostate cancer.
KEY EVIDENCE: Overall survival rates (HR = 0.95, P = 0.56) and progression-free survival (HR = 0.93, P = 0.32) did not differ significantly between groups.
APPROACH: Four randomised controlled trials involving 2,289 participants were analyzed using fixed or random-effects models based on data heterogeneity.
SIGNIFICANCE: Findings indicate the need for caution and further rigorous trials to evaluate the effectiveness of these combinations in metastatic castration-resistant prostate cancer.

Cite This Study

Syed et al. (2025) studied this question.

synapsesocial.com/papers/689a02b6e6551bb0af8cc30b https://doi.org/10.1186/s12885-025-14575-1

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals no significant benefit of immunotherapy-docetaxel combinations on overall survival in mCRPC, suggesting further trials are needed.

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider